E-mail

E-mail a Wiley Online Library Link

Brigette B. Y. Ma, Stephen L. Chan, Wing M. Ho, Wilson Lau, Frankie Mo, Edwin P. Hui, Charles Chan, Annette Poon, Rasalkar D. Dattatray, S. C. Cesar Wong, Ka F. To, Ann D. King, Anil Ahuja and Anthony T. C. Chan Intermittent versus continuous erlotinib with concomitant modified “XELOX” (q3W) in first-line treatment of metastatic colorectal cancer Cancer 119

Version of Record online: 1 OCT 2013 | DOI: 10.1002/cncr.28327

This phase 2 study is the first to evaluate the biological effect of different schedules of erlotinib in metastatic colorectal cancer. This study also demonstrates the prognostic utility of serum epidermal growth factor receptor ligands in erlotinib-treated patients with colorectal cancer.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

SEARCH